Nurix Posts $549.8M Q3 Profit on Roche Upfront, Advances Bexobrutideg into Phase 3
NRIX has more than doubled off its 52-week low of $9 on elevated volume (2.2× avg).
Summary
Nurix reported Q3 net income of $549.8M on $673.1M revenue, driven by the Roche collaboration upfront, and advanced bexobrutideg into Phase 3 while discontinuing NX-2127.
Key Events · Earnings and Guidance · NRIX
-
Q3 Profit Driven by Roche Upfront
Net income of $549.8M ($4.73 diluted EPS) on revenue of $673.1M, including $653.2M in license revenue from the Roche collaboration — a one-time recognition of the $700M upfront payment.
-
Cash Runway Extended to 2029
Cash, cash equivalents and marketable securities reached $1.1B as of August 31, 2026, up from $592.9M at fiscal year-end 2025, funding operations into the second half of 2029.
-
Bexobrutideg Enters Phase 3
First patient dosed in DAYBreak CLL-306, a registrational Phase 3 trial comparing bexobrutideg to pirtobrutinib in ~620 patients with relapsed/refractory CLL/SLL.
-
NX-2127 Discontinued
Nurix discontinued further clinical development of NX-2127 (zelebrudomide) as part of strategic prioritization; patients on treatment may continue with safety monitoring.
Analysis · NRIX · Life Sciences
A $549.8M quarterly profit marks a dramatic swing for Nurix, driven almost entirely by $653.2M in license revenue from the Roche collaboration — a one-time recognition of the $700M upfront. The underlying business remains a clinical-stage biotech burning cash on R&D, but the balance sheet is now fortified with $1.1B in cash and runway into 2029. Operationally, the company hit a major inflection point: first patient dosed in the registrational Phase 3 DAYBreak CLL-306 trial for bexobrutideg, its lead BTK degrader. The strategic decision to discontinue NX-2127 narrows the wholly owned pipeline but focuses resources on higher-conviction programs. The stock's reaction will hinge on whether investors view the Roche economics as transformative or simply a large one-time accounting event.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 36.5% of the 993 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRIX was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $9.00 to $28.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.